Edmond DE Rothschild Holding S.A. Purchases New Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Edmond DE Rothschild Holding initiated an approximately $10.6 million position in Gilead Sciences during the second quarter, while institutional investors collectively own 83.67% of the company.
• Analyst sentiment remains broadly positive: 24 analysts rate Gilead a Buy and five rate it a Hold, producing a “Moderate Buy” consensus and an average price target of $158.04.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above expectations, and declared a $0.82 quarterly dividend. Executives also sold shares under pre-arranged Rule 10b5-1 plans, including 28,000 shares sold by Chief Commercial Officer Johanna Mercier.

Edmond DE Rothschild Holding S.A. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 83,510 shares of the biopharmaceutical company's stock, valued at approximately $10,551,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Abacus FCF Advisors LLC bought a new position in Gilead Sciences in the 2nd quarter valued at $7,577,000. Madison Asset Management LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $505,000. Csenge Advisory Group bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $2,832,000. Shepherd Financial Partners LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $401,000. Finally, Johnson Financial Group Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $2,121,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on GILD shares. Rothschild & Co Redburn lowered their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a research report on Monday, July 27th. Maxim Group upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target for the company in a research note on Wednesday, May 20th. Weiss Ratings cut shares of Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Finally, HSBC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Twenty-four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $158.04.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares of the company's stock, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the transaction, the insider directly owned 118,234 shares of the company's stock, valued at approximately $16,273,727.76. This represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 82,000 shares of company stock valued at $10,837,860. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
• Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
• Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead's expanding HIV portfolio
• Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
• Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $147.60 on Thursday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The stock has a market cap of $183.02 billion, a PE ratio of -55.28 and a beta of 0.32. The stock has a fifty day moving average of $131.21 and a 200-day moving average of $136.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same quarter in the prior year, the firm posted $2.01 EPS. The firm's quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences's dividend payout ratio is currently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source